Archimed completes take-private of Esperion in deal valued up to $1.1 billion

Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc.

ESPR

0.00
  • ARCHIMED completed its acquisition of Esperion on July 13, 2026, valuing the deal at up to USD 1.1 billion on a fully diluted basis.
  • Esperion shareholders received USD 3.16 per share in cash, a 58% premium to the April 30, 2026 close.
  • Holders also received rights to contingent milestone payments totaling up to USD 100 million tied to future net sales performance.
  • Esperion shares stopped trading and were delisted from Nasdaq following the closing.
  • The acquisition was made through ARCHIMED’s MED Platform II fund, with unitranche debt provided by Pharmakon Advisors.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Archimed SAS published the original content used to generate this news brief on July 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.